Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP ‐1 Receptor Agonists: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials
Endocrinology, Diabetes & Metabolism · 2025-09 · 8 (5)
DOI: 10.1002/edm2.70113 ↗At a glance
Metaanalyse in Endocrinology, Diabetes & Metabolism, published online on 2025-09-23. Written by Jimmy Wen and 9 co-authors. Institution: College of Medicine, California Northstate University, Elk Grove, California, USA. Major MEDLINE topics: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents, Pancreatic Neoplasms. Cited 38 times so far (Crossref); 23 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Aims
This meta‐analysis evaluates the rates of pancreatitis/pancreatic cancer among glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) in randomised controlled trials (RCTs).
Methods
Following the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA), a systematic search was performed in PubMed, Embase, and Cochrane Library for GLP‐1 RA RCTs that evaluated pancreatitis/pancreatic cancer. A meta‐analysis was conducted to evaluate this risk; subgroup analysis was performed with and without background medications.
Results
62 studies utilising dulaglutide, exenatide, liraglutide, semaglutide, beinaglutide, retatrutide, or tirzepatide, with 66,232 patients, mean age of 58.3 years (14.4 to 68), and mean follow‐up of 43.5 weeks (1 to 198) were included in this study. Meta‐analysis showed a significantly increased risk of pancreatitis (RR: 1.44, 95% CI 1.09–1.89, p = 0.009), but not when stratified by background medications (RR: 1.28, 95% CI 0.87–1.87) and without background medications (RR: 1.37, 95% CI 0.91–2.05). Pancreatic cancer and GLP‐1 RA use showed no significant association (RR: 1.30, 95% CI 0.86–1.97). However, a significant increase was found with background medications (RR: 1.85, 95% CI 1.05–3.26, p = 0.03), but not without (RR: 0.81, 95% CI 0.43–1.55).
Conclusion
GLP‐1 RAs carry a slightly increased risk of pancreatitis, which is not significant when stratified by background medication use. Overall risk for pancreatic cancer was not observed, but a slight association was found when stratified with background medications. However, this difference is likely minimal, given the numerous studies excluded from the meta‐analysis where both treatment arms had zero events.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- College of Medicine, California Northstate University, Elk Grove, California, USA.
- University of California, Davis, California, USA.
ORCID profiles: Jimmy Wen, Ethan Bernstein
Cite
APA
Wen, J., Nadora, D., Bernstein, E., How-Volkman, C., Truong, A., Joy, B., Kou, M., Muttalib, Z., Alam, A., & Frezza, E. (2025). Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP ‐1 Receptor Agonists: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials. Endocrinology, Diabetes & Metabolism, 8(5). https://doi.org/10.1002/edm2.70113
Vancouver
Wen J, Nadora D, Bernstein E, How-Volkman C, Truong A, Joy B, et al. Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP ‐1 Receptor Agonists: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials. Endocrinology, Diabetes & Metabolism. 2025;8(5). doi:10.1002/edm2.70113
BibTeX
@article{Wen2025,
author = {Wen, Jimmy and Nadora, Denise and Bernstein, Ethan and How-Volkman, Christiane and Truong, Alina and Joy, Bethany and Kou, Megan and Muttalib, Zohaer and Alam, Arsh and Frezza, Eldo},
title = {Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP ‐1 Receptor Agonists: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials},
journal = {Endocrinology, Diabetes & Metabolism},
year = {2025},
volume = {8},
number = {5},
doi = {10.1002/edm2.70113}
}
EUVIMED